Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALKS Stock Forecast 2026-2027
$44.36
Current Price
$7.39B
Market Cap
Buy 13
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to ALKS Price Targets
+33.0%
To High Target of $59.00
+1.4%
To Median Target of $45.00
-23.4%
To Low Target of $34.00
ALKS Price Momentum
+0.2%
1 Week Change
+18.4%
1 Month Change
+50.8%
1 Year Change
+58.5%
Year-to-Date Change
-3.1%
From 52W High of $45.76
+76.2%
From 52W Low of $25.17
📊 TOP ANALYST CALLS
Did ALKS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alkermes is one of their latest high-conviction picks.
Latest ALKS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ALKS has a bullish consensus with a median price target of $45.00 (ranging from $34.00 to $59.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $44.36, the median forecast implies a 1.4% upside. This outlook is supported by 13 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALKS Analyst Ratings
13
Buy
3
Hold
0
Sell
ALKS Price Target Range
Low
$34.00
Average
$45.00
High
$59.00
Current: $44.36
Latest ALKS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALKS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 9, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $56.00 |
| May 13, 2026 | Baird | Outperform | Maintains | $N/A | |
| May 6, 2026 | UBS | Buy | Maintains | $N/A | |
| May 6, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 6, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 9, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Mar 24, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 26, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 26, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Feb 24, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Feb 20, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Nov 17, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Nov 13, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 13, 2025 | Deutsche Bank | Buy | Maintains | $N/A | |
| Nov 12, 2025 | Truist Securities | Buy | Reiterates | $N/A | |
| Nov 11, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Oct 29, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 29, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 27, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Oct 23, 2025 | Piper Sandler | Overweight | Reiterates | $N/A |
Alkermes PLC (ALKS) Competitors
The following stocks are similar to Alkermes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alkermes PLC (ALKS) Financial Data
Alkermes PLC has a market capitalization of $7.39B with a P/E ratio of 49.3x. The company generates $1.56B in trailing twelve-month revenue with a 9.8% profit margin.
Revenue growth is +28.2% quarter-over-quarter, while maintaining an operating margin of -0.2% and return on equity of +9.4%.
Valuation Metrics
Market Cap
$7.39B
Enterprise Value
$8.46B
P/E Ratio
49.3x
PEG Ratio
-0.1x
Price/Sales
4.7x
Growth & Margins
Revenue Growth (YoY)
+28.2%
Gross Margin
+84.3%
Operating Margin
-0.2%
Net Margin
+9.8%
EPS Growth
+28.2%
Financial Health
Cash/Price Ratio
+6.9%
Current Ratio
2.3x
Debt/Equity
90.3x
ROE
+9.4%
ROA
+4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alkermes PLC (ALKS) Business Model
About Alkermes PLC
What They Do
Develops innovative medicines in neuroscience.
Business Model
Alkermes generates revenue through the development and commercialization of biopharmaceutical products that address serious mental illnesses and addiction. It markets key products like Vivitrol and Aristada, and also engages in manufacturing and royalty agreements for other drugs. The company leverages proprietary technologies to create unique therapies, enhancing its competitive position in the market.
Additional Information
The company has a robust investigational pipeline, including promising candidates for narcolepsy and sleep disorders. With a strong research and development presence in Massachusetts and manufacturing capabilities in North Carolina, Alkermes is well-positioned to meet the healthcare demands of patients suffering from psychiatric and neurological disorders. Founded in 1987 and headquartered in Dublin, Ireland, it has a global reach in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,800
CEO
Mr. Richard F. Pops
Country
Ireland
IPO Year
1991
Website
www.alkermes.comAlkermes PLC (ALKS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Alkermes plc's investigational drug alixorexton received orphan drug designations from the FDA for idiopathic hypersomnia and from European regulators for narcolepsy and hypersomnia treatments.
Why It Matters
Alkermes' alixorexton receiving orphan drug designations enhances its market potential for treating narcolepsy and hypersomnia, potentially boosting the company's stock value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alkermes (NASDAQ: ALKS) is entering a critical phase, advancing its orexin agonist program to late-stage development, integrating Avadel, and preparing for a leadership transition.
Why It Matters
Alkermes' advancement in late-stage development and integration of Avadel signals potential growth and innovation, influencing future revenue and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Alkermes plc (ALKS) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, indicating ongoing engagement with investors and stakeholders in the healthcare sector.
Why It Matters
Alkermes' presentation at a major healthcare conference may signal upcoming developments or strategies that can influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AI and space are leading investment themes, but healthcare remains a defensive sector with stable demand, presenting differentiated opportunities for investors.
Why It Matters
Healthcare offers stability amid market volatility from AI and space trends, presenting a potential safe haven for investors seeking resilience in uncertain economic conditions.
Source: ETF Trends
Market Sentiment:
Positive
Quick Summary
Alkermes (ALKS) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters
Alkermes' recent earnings report can signal future performance, impacting stock valuation and investor sentiment. Upcoming developments may influence price movements and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Alkermes plc (Nasdaq: ALKS) will present 26 abstracts at the SLEEP 2026 conference, highlighting new data on its sleep medicine portfolio, including LUMRYZ® following the Avadel acquisition.
Why It Matters
Alkermes' presentation of new sleep medicine data could enhance its market position and drive stock value, reflecting potential growth in its sleep portfolio post-acquisition.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALKS Stock
What is Alkermes PLC's (ALKS) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Alkermes PLC (ALKS) has a median price target of $45.00. The highest price target is $59.00 and the lowest is $34.00.
Is ALKS stock a good investment in 2026?
According to current analyst ratings, ALKS has 13 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALKS stock?
Wall Street analysts predict ALKS stock could reach $45.00 in the next 12 months. This represents a 1.4% increase from the current price of $44.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alkermes PLC's business model?
Alkermes generates revenue through the development and commercialization of biopharmaceutical products that address serious mental illnesses and addiction. It markets key products like Vivitrol and Aristada, and also engages in manufacturing and royalty agreements for other drugs. The company leverages proprietary technologies to create unique therapies, enhancing its competitive position in the market.
What is the highest forecasted price for ALKS Alkermes PLC?
The highest price target for ALKS is $59.00 from at , which represents a 33.0% increase from the current price of $44.36.
What is the lowest forecasted price for ALKS Alkermes PLC?
The lowest price target for ALKS is $34.00 from at , which represents a -23.4% decrease from the current price of $44.36.
What is the overall ALKS consensus from analysts for Alkermes PLC?
The overall analyst consensus for ALKS is bullish. Out of 3 Wall Street analysts, 13 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are ALKS stock price projections?
Stock price projections, including those for Alkermes PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 10:09 AM UTC